Man or woman aged 18 or over;
- Patient suffering from a/mRCC, receiving sunitinib first-line treatment, as per SPC
recommendations;
- Resolution (grade ≤ 1 according to CTCAE version 4.03 of June 2010) of all acute toxic
effects due to radiotherapy or surgical procedure prior to initiation of sunitinib;
- Patient who can be monitored for 6 months.
- Female patient of child-bearing age using a form of contraception during treatment
with Sunitinib and for at least 28 days after termination of treatment with Sunitinib;
- Patient having signed his/her consent form;
- Patient affiliated with a social security scheme.
Non-inclusion criteria
- Patient participating in a clinical trial during sunitinib treatment;
- Patient managed by a home hospitalisation service during sunitinib treatment;
- Patient taking part in therapeutic education programmes, or benefiting from nursing
consultation, or from any other significant treatment support and likely to impact
adverse event management.
- Patient untreated and/or symptomatic brain metastases prior to sunitinib initiation;
- Patient refusing the use of his/her personal data.
- Patient with an ECOG performance status upon inclusion > 2;
- Patient presenting with a serum creatinine level >1.5 times the upper limit of the
normal level;
- Patient presenting with a bilirubin level > 2 mg/dl, aspartate transaminase (ASAT) or
alanine transaminase (ALAT) >2.5 times the upper limit of the normal value, or >5
times the upper limit of the normal value in the presence of liver metastases upon
initiation of sunitinib treatment.
- Patients who are staff members of a centre involved in the study, or close to one of
the staff members of a centre directly involved in conducting the study, or patients
employed by Pfizer and involved in conducting the study
Man or woman aged 18 or over;
- Patient suffering from a/mRCC, receiving sunitinib first-line treatment, as per SPC
recommendations;
- Resolution (grade ≤ 1 according to CTCAE version 4.03 of June 2010) of all acute toxic
effects due to radiotherapy or surgical procedure prior to initiation of sunitinib;
- Patient who can be monitored for 6 months.
- Female patient of child-bearing age using a form of contraception during treatment
with Sunitinib and for at least 28 days after termination of treatment with Sunitinib;
- Patient having signed his/her consent form;
- Patient affiliated with a social security scheme.
Non-inclusion criteria
- Patient participating in a clinical trial during sunitinib treatment;
- Patient managed by a home hospitalisation service during sunitinib treatment;
- Patient taking part in therapeutic education programmes, or benefiting from nursing
consultation, or from any other significant treatment support and likely to impact
adverse event management.
- Patient untreated and/or symptomatic brain metastases prior to sunitinib initiation;
- Patient refusing the use of his/her personal data.
- Patient with an ECOG performance status upon inclusion > 2;
- Patient presenting with a serum creatinine level >1.5 times the upper limit of the
normal level;
- Patient presenting with a bilirubin level > 2 mg/dl, aspartate transaminase (ASAT) or
alanine transaminase (ALAT) >2.5 times the upper limit of the normal value, or >5
times the upper limit of the normal value in the presence of liver metastases upon
initiation of sunitinib treatment.
- Patients who are staff members of a centre involved in the study, or close to one of
the staff members of a centre directly involved in conducting the study, or patients
employed by Pfizer and involved in conducting the study